Dyne Therapeutics — Third Quarter 2026 Earnings Summary

Dyne Therapeutics reported a net loss of $193.6 million for the third quarter of 2026, driven by increased research and development expenses for its z-rostudirsen and z-basivarsen programs. The company's Biologics License Application for z-rostudirsen in exon 51 Duchenne muscular dystrophy is under priority review by the FDA, with a target action date of January 21, 2027. Additional one-year clinical data from the Phase 1/2 ACHIEVE trial for z-basivarsen in myotonic dystrophy type 1 demonstrated functional improvements, while topline data from the registrational expansion cohort is expected in the first quarter of 2027. Dyne maintains a cash position of $1.134 billion as of September 30, 2026, which is projected to fund operations through the second quarter of 2028.